gms | German Medical Science

28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

24. bis 27.11.2004, Hannover

Adding HCTZ to olmesartan therapy improves 24-hour blood pressure control and response rates in patients with mild-to-moderate hypertension

Erweiterung der Olmesartan-Therapie um HCTZ verbessert die 24h- Blutdruckwerte und Ansprechraten

Meeting Abstract (Hypertonie 2004)

Suche in Medline nach

  • L. Sellin - Klinikum der Ruhr-Universität Bochum (Herne, D)
  • P. Laeis - Sankyo (München, D)
  • L.C. Rump - Klinikum der Ruhr-Universität Bochum (Herne, D)

Hypertonie 2004. 28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Hannover, 24.-27.11.2004. Düsseldorf, Köln: German Medical Science; 2005. Doc04hochP108

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2004/04hoch108.shtml

Veröffentlicht: 10. August 2005

© 2005 Sellin et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: To compare the effects of adding hydrochlorothiazide (HCTZ; 12.5 mg or 25 mg) or placebo to olmesartan medoxomil 20 mg on blood pressure in patients whose essential hypertension was inadequately controlled on olmesartan monotherapy.

Design: Partially-randomised, placebo-controlled, multi-centre, prospective study.

Setting: Primary care investigational centres.

Patients: Male and female patients >=18 years with mean sitting diastolic BP (dBP) of 100-115 mmHg, mean sitting systolic (sBP) greater than 150 mmHg, mean 24-hour dBP of at least 84 mmHg, and at least 30% of dBP daytime readings >90 mmHg.

Interventions: Four weeks of initial single-blind treatment with olmesartan medoxomil 20 mg once daily, followed in non-responders by 8 weeks of randomised double-blind treatment with placebo or HCTZ (12.5 mg or 25 mg) once-daily added to olmesartan therapy.

Results: The primary efficacy parameter, mean daytime dBP, decreased significantly more with HCTZ 25 mg (p=0.0012) than with placebo. Relative to placebo, significantly greater decreases in mean 24-hour dBP and sBP were produced by the addition of HCTZ 12.5 mg (-1.9 mmHg, p=0.0167 and -3.9 mmHg, p=0.0018, respectively) and 25 mg (-3.7 mmHg and -7.4 mmHg respectively, p <0.0001 for both). Response rates (mean daytime dBP assessed by ABPM £85 mmHg) approximately doubled following the addition of HCTZ (12.5 mg = 57.6% and 25 mg =69.5%). All treatments were well tolerated.

Conclusion: For patients whose blood pressure cannot be adequately controlled with olmesartan medoxomil monotherapy, the addition of HCTZ provides significant additional 24-h blood pressure-lowering efficacy in patients without affecting tolerability.